From the 1st of June the British Hospital received the corresponding authorizations through the Oncological Gynecology team of the Gynecology Department to become a reference center in Uruguay to carry out the international collaborative clinical research protocol TUBA WISP II.
This study aims to reduce the incidence of ovarian cancer in women with genetic predisposition (pathogenic mutations in BRCA1, BRCA2, RAD51C, RAD51D and BRIP1 genes) with less hormonal impact than the currently recommended strategy.
TUBA-WISP II is an international study designed together between the MD Anderson Cancer Center (United States) and the University of Radboudumc (The Netherlands). Nowadays 28 centres participate worldwide (Italy, Spain, Austria, Holland, Norway, Poland, USA and Mexico) and the British Hospital is the first in South America.
Through a genetic risk assessment it is possible to determine if the application of the TUBA WISP II protocol is appropriate, which proposes a progressive surgical treatment, offering the patient a personalized approach that reduces the appearance of symptoms of early menopause compared to the strategy current situation, closely accompanying and monitoring their physical, mental and emotional well-being.
Drs. Santiago Scasso and Joel Laufer who are the leading researchers for the study will coordinate the referral treatment and the follow-up of each case working together with Genetics, Medical Oncology, Imaging and Mastology,
We congratulate this achievement which makes it possible for our hospital scheme members to participate in jobs that allows them to offer world-class treatments.
For further information:
Reference Adm. Analía López. Department of Gynecology - Responsible investigator. Gynecologist Oncologist Dr. Santiago Scasso | Tel: 24871020 ext. 3601